Nanovibronix Inc
Change company Symbol lookup
Select an option...
NAOV Nanovibronix Inc
ETON Eton Pharmaceuticals Inc
LXRX Lexicon Pharmaceuticals Inc
BVS Bioventus Inc
TDS-U Telephone and Data Systems Inc
ELEV Elevation Oncology Inc
FRZA Forza X1 Inc
SIEN Sientra Inc
PMGM Priveterra Acquisition Corp
NVFY Nova LifeStyle Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NanoVibronix, Inc. is a medical device company. The Company is focused on developing noninvasive biological response-activating devices utilizing its low-intensity surface acoustic wave (SAW) technology. Its primary products consist of UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which markets in the United States under Food and Drug Administration (FDA) policy of enforcement discretion during the COVID-19 pandemic and is undergoing clinical testing. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD and PainShield Plus.

Day's Change
-0.1377 (-3.97%)
B/A Size
Day's High
Day's Low

Today's volume of 1,219 shares is on pace to be in-line with NAOV's 10-day average volume of 6,672 shares.


Warner Bros Discovery stock finds two new bulls in the face of 'draconian' expectations for linear TV

8:26 am ET March 17, 2023 (MarketWatch)

By Emily Bary

Wolfe Research analyst says 'the skeletons in Warner's closet have been accounted for'

Warner Bros. Discovery Inc. shares were basking in the love of two new bulls Friday as analysts at Wolfe Research and Wells Fargo changed their tune on the media giant.

"After a '22 rife with negative surprises around the Warner-Discovery integration & TV advertising market, and after two rounds of forecast reductions, today's expectations are attractive to underwrite," Wolfe's Peter Supino wrote as he upgraded the name to outperform from peer perform. "Networks segment estimates & valuation bake in cyclical & secular headwinds, and we believe that the skeletons in Warner's closet have been accounted for."

Supino said that investors seem too pessimistic about the company's networks business, with WBD's stock price (WBD) currently in a "draconian pay-TV scenario."

"We're bearish on the linear pay-TV outlook, but the Networks generate lots of cash and will for many years," he wrote. "WBD's scale, licensing strategy, & HBO/Turner synergies provide some cushion. Net-net, less extreme, but still very bearish decline assumptions drive stock upside."

He anticipates that Warner executives will be able to drive gross leverage down from his estimate of 3.9x at the end of 2023 to 3.0x by the end of 2024.

Warner shares were up more than 4% in Friday's premarket action.

Wells Fargo's Steven Cahall discussed leverage expectations as well in his own upgrade of WBD shares to overweight from equal weight. Both analysts noted that WBD's management has linked executive compensation to progress on deleveraging.

"We threw everything and the kitchen sink at a Downside Case scenario for WBD, and it still delevers to 3x by '25E," Cahall wrote. "We now have conviction in [free-cash flow] to limit downside, while the stock has asymmetric upside."

Cahall acknowledged that "recent macro events might make levered equities seem worse," but he feels more optimistic about WBD's positioning lately due to the company's execution and potential for synergies. WBD was formed by the merger of Discovery and WarnerMedia after AT&T spun off the latter last spring.

There's more to the story than just deleveraging, he added: "We think DTC [direct-to-consumer]/HBO is currently undervalued vs peers given the near-term break-even and future profit ramp."

Both analysts now have $20 price targets on the stock. Supino didn't have a price target on the stock previously, while Cahall assigned it a $13 target prior.

-Emily Bary

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

March 17, 2023 08:26 ET (12:26 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.